{"id":"placebo-for-olaparib","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL521686","moleculeType":"Small molecule","molecularWeight":"434.47"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebos are inert substances used as controls in clinical trials to establish the efficacy of the active drug being tested. In this case, it serves as the control arm in a Phase 3 trial comparing olaparib (a PARP inhibitor) to placebo. Any observed effects in the placebo group are attributable to the placebo effect or natural disease progression.","oneSentence":"A placebo contains no active pharmaceutical ingredient and produces no direct pharmacological effect.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:27:15.463Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Control arm in Phase 3 clinical trial for olaparib"}]},"trialDetails":[{"nctId":"NCT04858334","phase":"PHASE2","title":"APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-06-22","conditions":"Pancreatic Acinar Cell Carcinoma, Pancreatic Adenosquamous Carcinoma, Pancreatic Squamous Cell Carcinoma","enrollment":152},{"nctId":"NCT07018622","phase":"PHASE2","title":"Protecting the Kidney's Proximal Tubules From Platinum-Based Chemotherapy Toxicity","status":"RECRUITING","sponsor":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran","startDate":"2025-05-07","conditions":"Solid Tumors, Cisplatin Nephrotoxicity","enrollment":46},{"nctId":"NCT04884360","phase":"PHASE3","title":"D9319C00001- 1L OC Mono Global RCT","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2021-05-31","conditions":"Ovarian Cancer","enrollment":366},{"nctId":"NCT03976362","phase":"PHASE3","title":"A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008/KEYLYNK-008)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-06-28","conditions":"Carcinoma, Squamous Cell, Non-small-cell Lung","enrollment":851},{"nctId":"NCT03775486","phase":"PHASE2","title":"Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2018-12-21","conditions":"Non-small Cell Lung Cancer NSCLC","enrollment":401},{"nctId":"NCT03459846","phase":"PHASE2","title":"A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2018-03-16","conditions":"Urinary Bladder Neoplasms","enrollment":154},{"nctId":"NCT04269200","phase":"PHASE3","title":"Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2020-05-05","conditions":"Endometrial Neoplasms","enrollment":805},{"nctId":"NCT01844986","phase":"PHASE3","title":"Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2013-08-26","conditions":"Newly Diagnosed, Advanced Ovarian Cancer, FIGO Stage III-IV","enrollment":450},{"nctId":"NCT03740165","phase":"PHASE3","title":"Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-12-18","conditions":"Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms","enrollment":1367},{"nctId":"NCT04380636","phase":"PHASE3","title":"Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-07-06","conditions":"Lung Neoplasms, Carcinoma, Non-Small-Cell Lung","enrollment":870},{"nctId":"NCT04624204","phase":"PHASE3","title":"Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-12-08","conditions":"Small Cell Lung Cancer","enrollment":672},{"nctId":"NCT03737643","phase":"PHASE3","title":"Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2019-01-04","conditions":"Advanced Ovarian Cancer","enrollment":1407},{"nctId":"NCT01788332","phase":"PHASE2","title":"Parp Inhibitor in Advanced Non-Small Cell Lung Cancer (PIN)","status":"UNKNOWN","sponsor":"Lisette Nixon","startDate":"2014-01","conditions":"Non-small Cell Lung Cancer","enrollment":70}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":171,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Placebo"],"phase":"phase_3","status":"active","brandName":"Placebo for olaparib","genericName":"Placebo for olaparib","companyName":"Merck Sharp & Dohme LLC","companyId":"merck","modality":"Small molecule","firstApprovalDate":"","aiSummary":"A placebo contains no active pharmaceutical ingredient and produces no direct pharmacological effect. Used for Control arm in Phase 3 clinical trial for olaparib.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}